Royal DSM partners with Amyris to develop a low cost nutrition molecule


In California, Amyris, Inc. entered into its first product development and production agreement to develop a food and nutrition molecule for Koninklijke DSM N.V.

“We are very excited to partner with DSM on our first product development and production agreement,” said John Melo, Amyris President & CEO. “This is the first of what are expected to be several highly disruptive products addressing major markets where, together, we can leverage Amyris’s technology platform to reduce cost for products DSM then takes to market in a cost-advantaged position.”

DSM will partner with Amyris and fund the development of the technology to produce the specific molecule that Amyris will then scale and supply long term to deliver improved performance while growing its business.  DSM will take the molecule to market utilizing its channel and market access and take advantage of Amyris’s biotechnology production, which provides a lower cost of production than currently available.